Inquiry Basket
Loading ......
Human metapneumovirus (hMPV) is a significant respiratory pathogen first isolated in the Netherlands in 2001. Belonging to the family Paramyxoviridae, subfamily Pneumovirinae, hMPV is a pleomorphic, enveloped virus with a negative-sense, single-stranded RNA genome of approximately 13.3 kb. It is a leading cause of acute respiratory tract infections (ARTIs) worldwide, disproportionately affecting infants, older adults, and immunocompromised individuals.
The clinical spectrum of hMPV infection ranges from mild upper respiratory symptoms—cough, nasal congestion, and fever—to severe lower respiratory tract disease, including bronchiolitis and pneumonia. In vulnerable populations, hMPV frequently leads to prolonged hospitalization and increased healthcare burden. Despite its substantial disease burden, no licensed vaccine or specific antiviral therapy is currently available, and clinical management remains largely supportive.
The hMPV genome encodes nine major proteins organized in the 3' to 5' order: N (nucleoprotein), P (phosphoprotein), M (matrix protein), F (fusion glycoprotein), M2-1 (transcription elongation factor), M2-2 (RNA synthesis regulatory factor), SH (small hydrophobic protein), G (attachment glycoprotein), and L (RNA-dependent RNA polymerase).
Fusion (F) Protein: A class I fusion glycoprotein and the primary target for vaccine development. The F protein mediates viral entry by driving the fusion of the viral envelope with the host cell membrane. In its native, prefusion conformation, the F trimer presents multiple neutralizing epitopes that are the principal targets of protective antibodies. Stabilization of F in its prefusion state—analogous to the strategy employed for RSV—has emerged as the central design principle for next-generation hMPV vaccines.
Attachment (G) Protein: A heavily glycosylated type II membrane protein that facilitates viral attachment to host cells. Unlike the F protein, the G protein is highly variable between strains and does not elicit potent neutralizing antibodies, making it a secondary vaccine target.
Small Hydrophobic (SH) Protein: A viroporin involved in immune evasion. The SH protein modulates host inflammatory responses and has been implicated in inhibition of the NF-κB pathway.
Nucleoprotein (N): The most abundant structural protein, encapsidating the viral RNA genome. The N protein is highly immunogenic and serves as the primary target for diagnostic serological assays.
Fig. 1 hMPV virion structure and genome organization
hMPV employs sophisticated strategies to evade and subvert host immunity, contributing to its ability to cause recurrent infections throughout life:
Live-attenuated hMPV vaccines are engineered by introducing mutations that reduce viral replication while maintaining immunogenicity. A common approach involves deleting or altering the SH and G genes, which are dispensable for viral replication in vitro but critical for immune evasion in vivo.
Key Candidate: The Metavac® platform (Vaxxel) utilizes an hMPV ΔSH backbone. Intranasal administration has demonstrated robust mucosal immunity and protection in preclinical models. A bivalent candidate (Metavac®-RSV) expressing both hMPV F and RSV F has shown strong immunogenicity and protection against lethal challenges in murine models, with Phase 1 initiation planned for 2026.
NIAID B/HPIV3 Vectored Vaccines: Two candidates, B/HPIV3/HMPV-PreF-A and B/HPIV3/HMPV-F-B365, use a bovine/human parainfluenza virus type 3 backbone to express hMPV F protein. These are currently in Phase 1 trials evaluating safety and immunogenicity in children aged 24--60 months.
Subunit vaccines present recombinant viral proteins—most commonly the F protein in its stabilized prefusion conformation—without exposing the host to live virus. Virus-like particle (VLP) platforms further enhance immunogenicity by displaying antigens in a dense, repetitive array that mimics native viral architecture.
IVX-A12 (AstraZeneca/Icosavax): The most advanced hMPV vaccine candidate, IVX-A12 is a bivalent VLP vaccine targeting both RSV and hMPV. It comprises two intramuscularly administered VLPs: RSV pre-F (IVX-121) and hMPV pre-F (IVX-241). Phase 1 trials in adults aged 60--75 demonstrated robust increases in neutralizing antibody titers against both viruses with no safety concerns. Phase 2 data in older adults showed robust immune responses across all RSV and hMPV subgroups. The candidate is Phase 3-ready and has received FDA Fast Track Designation.
VXB-241 (Vicebio): A bivalent subunit vaccine utilizing proprietary molecular clamp technology, which constrains viral fusion proteins in their native prefusion conformation. A Phase 1 trial for VXB-241 began in Q3 2024, with interim readouts planned for 2025.
Building on the transformative success of COVID-19 mRNA vaccines, nucleic acid platforms encoding stabilized hMPV F proteins are in active development.
mRNA-1653 (Moderna): The first combination mRNA vaccine simultaneously targeting hMPV and parainfluenza virus type 3 (PIV3). It encodes two distinct nucleoside-modified mRNAs—the full-length F proteins of hMPV and PIV3—co-formulated in lipid nanoparticles. Phase 1 evaluations in healthy adults and children aged 18--55 months demonstrated an acceptable safety profile and significant increases in neutralizing antibody titers for both viruses after a single dose.
mRNA-1365 (Moderna): A bivalent mRNA vaccine targeting RSV and hMPV, designed for pediatric indications. Preclinical studies have demonstrated broad neutralizing antibody responses.
Sanofi Pasteur mRNA Platform: Sanofi has launched clinical trials in 2024 for both bivalent (RSV/hMPV) and trivalent (RSV/hMPV/HPIV3) F protein-based mRNA vaccines, leveraging their established LNP delivery expertise.
Fig. 2 HIV replication cycle
hMPV circulates as two major genetic lineages, A and B, each subdivided into subtypes (A1, A2, B1, B2). The F protein, while more conserved than the G protein, still exhibits inter-lineage variation that may affect vaccine-induced neutralization breadth. Current candidates target the prefusion F conformation to maximize cross-lineage protection.
As detailed above, hMPV devotes multiple gene products (G, SH, M2-2) to actively antagonize host innate immunity. Vaccines must overcome this immunosuppressive environment to induce robust and durable protective responses.
Following the historical precedent of formalin-inactivated RSV vaccines, there is concern that certain inactivated hMPV vaccines could potentially prime for enhanced disease upon natural infection. This risk has strongly favored the development of live-attenuated and prefusion-stabilized subunit platforms over inactivated whole-virus approaches.
Infants—the primary target population for hMPV vaccination—have immature immune systems and are subject to interference from maternal antibodies. Achieving durable protection in this cohort remains a central challenge, informing the development of maternal immunization and early-life vaccination strategies.
Natural hMPV infection fails to establish long-term protective immunity. An ideal vaccine must induce durable systemic neutralizing antibodies alongside mucosal secretory IgA (sIgA) to block infection at the respiratory portal of entry.
The hMPV vaccine field is converging on several strategic priorities:
Human metapneumovirus represents a critical unmet need in respiratory infectious disease prevention. While no vaccine is yet licensed, the pipeline is robust and diverse, spanning VLP, mRNA, live-attenuated, and subunit platforms. The most advanced candidate, IVX-A12, is Phase 3-ready with FDA Fast Track status, offering the prospect of the first approved hMPV vaccine in the near term.
The parallel challenges and successes of RSV vaccinology have accelerated hMPV vaccine design, particularly in the realm of prefusion F protein stabilization. As clinical data mature and combination vaccines advance, the integration of hMPV immunization into routine respiratory disease prevention strategies appears increasingly achievable.
References
Loading ......
